Bevacizumab in Advanced Kidney Cancer: Another Treatment Gives Benefit in First Line
BERNARD ESCUDIER, Gustave Roussy Institute, Villejuif
COMMENT: DEAN BAJORIN, Memorial Sloan-Kettering Cancer Center, New York
Doctors can now use bevacizumab for first line therapy in advanced kidney cancer. That’s according to Bernard Escudier of the Gustave Roussy Institute, who presented phase III data at ASCO. But since the drug was tested against interferon, how might it compare with sunitinib, another targeted therapy that received a ringing endorsement at last year’s annual meeting? Peter Goodwin found out more in Chicago.
Benefit from Radium-223 in Hormone Refractory Prostate Cancer?
OYVIND BRULAND, The Norwegian Radium Hospital, Oslo
A novel treatment involving a bone-seeking radionuclide has shown promising results in a randomised phase II trial for men with hormone refractory prostate cancer and bone metastases. Sarah Maxwell found out more from Oyvind Bruland of the Norwegian Radium Hospital in Oslo.
Cetuximab Up-Front Significantly Increases Survival in Head and Neck Cancer
JAN VERMORKEN, University Hospital Antwerp
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
Patients with head and neck squamous cell carcinoma who receive cetuximab in addition to their platinum based chemotherapy have a clear survival advantage. This was the headline result coming out of the EXTREME trial announced to the ASCO meeting in Chicago. Sarah Maxwell heard more from chief author Jan Vermorken of the University of Antwerp.
Can Flaxseed Slow Prostate Cancer Growth?
WENDY DENMARK-WAHNEFRIED, Duke University, Durham
COMMENT: BRUCE CHESON, Georgetown University, Washington DC
Flaxseed, a dietary supplement rich in lignan and omega-3 fatty acids, could help slow down the growth of prostate tumors. This came out of a phase II study presented at ASCO by Wendy Demark-Wahnefried of Duke University Medical Center in Durham, North Carolina. Derek Thorne heard more details from her in Chicago.